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Background: As biliary tract cancer is a rare malignancy, prognostic and predictive markers of 
advanced biliary tract cancer have not been clearly elucidated. The purpose of this study is to 
evaluate the prognostic and predictive role of tumor marker, tumor marker change and gene 
polymorphism in advanced biliary tract cancer. 
Patients and methods: Patients with pathologically proven metastatic or relapsed biliary tract 
cancer who had undergone first line S-1 plus cisplatin chemotherapy were enrolled. Time to 
progression (TTP) and overall survival (OS) were compared. 
Results: Among a total of 104 patients, 69 (66.3%) patients had elevated baseline CA 19-9 level 
and 40 (38.5%) patients had elevated baseline CEA level. Eighty patients (77%) had either 
elevated CEA or CA 19-9 level. Multivariate analysis revealed that patients with elevated 
baseline CEA level have poorer TTP and OS compared to patients with normal CEA level. 
Baseline CA 19-9 level did not influence TTP or OS in multivariate analysis. Eleven germline 
polymorphisms within 4 genes were analyzed using polymerase chain reaction–restriction 
fragment length polymorphism methods. Three genes were involved in DNA damage repair and 
other single gene was associated with fluoropyrimidine. Only XRCC1 exon 194 gene had a 
negative prognostic role in terms of OS. Multivariate analysis revealed that XRCC1 194 C/T 
and T/T had a poor OS compared to C/C (adjusted HR 1.59, p = 0.048). In patients with 
elevated baseline CA 19-9, decline ≥ 30% after first cycle of chemotherapy showed prolonged 
TTP (5.0 vs. 8.6 months, p = 0.015) and OS (7.9 vs. 18.4 months, p < 0.001) as well as better 
chemotherapy response. Similar results were also obtained with CEA level change.  
Conclusions: Baseline CEA or XRCC1 codon 194 polymorphism had a prognostic role in 
advanced biliary tract cancer. CA 19-9 or CEA decline ≥ 30% after first cycle of chemotherapy 
serves as a positive predictive and prognostic marker.  
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Biliary tract cancer includes intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, 
gall bladder cancer, and ampulla of Vater cancer. While incidence of biliary tract cancer is low 
in Western countries (2 to 3 persons/100,000 population per year), their incidence is relatively 
high in Asian countries (4 to 6 persons /100,000 population per year) (1, 2). Complete resection 
is the only option for the cure of biliary tract cancer but only 10% of the patients are diagnosed 
at early stage of disease and are considered for curative resection (3). For unresectable or 
metastatic biliary tract cancer, chemotherapy has shown significant benefit compared to best 
supportive care only (4, 5). In a randomized controlled phase III study, gemcitabine plus 
cisplatin showed improved Overall survival (OS) and progression free survival (PFS) compared 
to gemcitabine alone (6). Although gemcitabine plus cisplatin is considered as a standard of care 
in first-line setting, this regimen has not been compared head to head with other 
fluoropyrimidine-based regimen in phase III studies. In a phase II study, combination of S-1 and 
cisplatin showed comparable efficacy and favorable safety compared to gemcitabine plus 
cisplatin in advanced biliary tract cancer (7). Gemcitabine-based or fluoropyrimidine-based 
combinations are the standard chemotherapy regimen for advanced biliary tract cancer (6, 8-10). 
Despite the progress in chemotherapy, prognosis of biliary tract cancer remains poor with 
median OS of 5 to 15 month and only 15 to 40% of patient shows response to chemotherapy 
(11). Selection of patients who might benefit from specific chemotherapy is important. In 
addition, early assessment of treatment efficacy can help physician’s clinical decision and can 
prevent patients from unnecessary treatment. Metastatic disease, intrahepatic 
cholangiocarcinoma, liver metastasis, Eastern Cooperative Oncology Group (ECOG) 
performance status and alkaline phosphatase (ALP) level were identified as a prognostic factor 
in advanced BTS (12). However predictive and prognostic role of other factors including 
carcinoembryonic antigen (CEA), carbohydrate Antigen (CA) 19-9 and gene polymorphism has 
not been clearly elucidated in advanced biliary tract cancer. A number of studies have 
investigated the relationships between genetic polymorphism and efficacy of distinct 
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chemotherapy agent. The aim of our study is to evaluate the predictive and prognostic role of 
baseline CEA, baseline CA 19-9, tumor marker changes and gene polymorphisms, using our 
homogenous cohort of patients who has undergone first-line S-1 plus cisplatin chemotherapy in 
advanced biliary tract cancer. S-1 is an oral fluoropyrimidine agent containing tegafur, gimeracil 
and oteracil potassium. The mechanism of action of fluoropyrimidine is through the inhibition 
of thymidylate synthase (TS). Cisplatin is a platinum agent, which inhibits DNA synthesis by 
the formation of DNA cross-links. We chose 4 genes for polymorphism analysis, three genes 
were associated with DNA damage repair and other gene was TS. 
 
MATERIAL AND METHODS 
 
Patients and treatment 
Patients (N = 104) with pathologically proven unresectable, metastatic, or relapsed biliary tract 
adenocarcinoma participated in a phase II trial of S-1 and cisplatin were included (13). At least 
one measurable lesion according to the Response Evaluation Criteria in Solid tumors (RECIST) 
was required. Eligibility criteria included age over 18, ECOG performance status of 0 to 2, no 
prior chemotherapy or radiotherapy, adequate bone marrow, hepatic, and renal function 
[absolute neutrophil count (ANC) ≥ 1.5 x 109/l, platelet count ≥ 100 x 109/l, total bilirubin ≤ 2 x 
upper limit of normal (ULN), serum transaminases ≤ 2.5 x ULN, alkaline phosphatase ≤ 5 x 
ULN, serum creatinine ≤ 1.5 x ULN or actual or calculated creatinine clearance ≥ 60 ml/min]. 
Written informed consent was obtained from each patient before enrollment and the protocol 
was approved by the institutional review board of the Seoul National University Hospital, Seoul, 
Korea. 
S-1 was administered orally at a dose of 40 mg/m2 twice daily for 14 days, followed by a 7-day 
rest period. Cisplatin was given as a 90–minute infusion on day 1 of each cycle at a dose of 60 
mg/m2. Treatment was repeated every 3 weeks until disease progression, unacceptable toxicity, 
or withdrawal of patient consent. Drug administration was delayed until ANC ≥ 1.5 x 109/l, 
platelet count ≥ 75 x 109/l, and recovery from non-hematologic toxicity to baseline or less than 
or equal to grade 1. S-1 was reduced by 25% on all subsequent cycles for febrile neutropenia, 
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grade 4 neutropenia, grade 3/4 thrombocytopenia, greater than or equal to grade 3 non-
hematologic toxic effects. Cisplatin was reduced by 25% for febrile neutropenia and greater 
than or equal to grade 3 non-hematologic toxic effects. 
Best tumor response was assessed using RECIST criteria, with computed tomography (CT) 
scans (14). CT scan was made at baseline and every two cycles (6 weeks) thereafter. Medical 
history taking, physical examination, measurement of the CEA, CA 19-9 level and toxicity 
evaluation was made on every cycle. Toxicity was measured according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events, version 3.0. 
 
Genotype analysis 
 For the analysis of germline genetic polymorphisms, peripheral blood samples were obtained 
from patients with informed consent. Genomic DNA was extracted form peripheral blood 
samples using QIAmp DNA blood kit (Qiagen,Valencia, CA, USA). Eleven polymorphisms in 
four genes were investigated. The following polymorphisms were analyzed using polymerase 
chain reaction–restriction fragment length polymorphism methods: thymidylate synthase (TS; 
28-bp repeat in the enhancer region, G⁄C polymorphism in the second repeat, 6-bp deletion in 
the 3’-untranslated region [UTR]), excision repair cross-complementation group 1 (ERCC1; 
Asn118Asn, C8092A), Xeroderma pigmentosum group D (XPD; Arg156Arg, Asp312Asn, 
Lys751Trp), and X-ray repair cross-complementing group 1 (XRCC1; Arg194Trp, Arg280His, 
Arg399Gln). Primer sequences and restriction enzymes are listed in Table 1.  
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Table 1. Primer sequences and restriction enzymes 




















TS 28-bp repeat in 
enhancer region 




 G ⁄ C SNP in 
second repeat 




 6-bp deletion in  
3’-UTR 
Forward: CAAATCTGAGGGAGCTGAGT Dra I 














ERCC1 Asn118Asn Forward: TCATCCCTATTGATGGCTTCTGCCC BsrD I 
  Reverse: GACCATGCCCAGAGGCTTCTCATAG  
 C8092A Forward: CAGAGACAGTGCCCCAAGAG Mbo II 
  Reverse: GGGCACCTTCAGCTTTCTTT  
XPD Arg156Arg Forward: CACACCTGGCTCATTTTTGTAT Tfi I 
  Reverse: TCATCCAGGTTGTAGATGCCA  
 Asp312Asn Forward: 
CTGTTGGTGGGTGCCCGTATCTGTTGGTCT 
Sty I 
  Reverse: 
(TAATA)TCGGGGCTCACCCTGCAGCACTTCCT 
 
 Lys751Trp Forward: GCCCGCTCTGGATTATACG Pst I 
  Reverse: CTATCATCTCCTGGCCCCC  
XRCC1 Arg194Trp Forward: GCCCCGTCCCAGGTA Pvu II 
  Reverse: AGCCCCAAGACCCTTTCACT  
 Arg280His Forward: TTGACCCCCAGTGGTGCTAA Rsa I 
  Reverse: AGTCTGCTGGCTCTGGGCTGG  
 Arg399Gln Forward: TTGTGCTTTCTCTGTGTCCA Msp I 
  Reverse: TCCTCCAGCCTTTTCTGATA  
Abbreviations: ERCC1, Excision repair cross-complementation group 1; TS, Thymidylate 
synthase; XPD, Xeroderma pigmentosum group D ; XRCC1, X-ray repair cross-complementing 




The primary objective of this study was to investigate the effect of serum tumor marker (CEA, 
CA 19-9), tumor marker change and gene polymorphism status on the treatment outcome of 
advanced biliary tract cancer patients treated with S-1 and cisplatin chemotherapy. Categorical 
variables were compared using chi-square test. Time to progression (TTP) and OS were 
calculated using the Kaplan-Meier method and comparisons were made using the log-rank tests. 
Hazard ratios (HR) were calculated using the Cox proportional hazard model. In order to adjust 
for the baseline characteristics, we used Cox proportional hazard model in a forward stepwise 
manner with variable as followings: initial presentation with metastatic disease, intrahepatic 
cholangiocarcinoma, liver metastasis, ECOG performance status, ALP level, CEA level, CA 19-
9 level and gene polymorphism. Gene polymorphisms with p-values of less than 0.10 in the 
univariate analysis were included in the multivariate analysis. Two-sided p-values of less than 
0.05 were considered statistically significant. Statistical analysis was performed with SPSS 






A total of 104 patients with advanced biliary tract cancer, treated with S-1 and cisplatin 
chemotherapy were included from January 2005 to December 2008. Baseline characteristics are 
summarized in Table 2. Tumor type was intrahepatic cholangiocarcinoma in 57, gall bladder 
cancer in 33, extrahepatic cholangiocarcinoma in 11 and ampulla of vater cancer in 3 patients. 
Presentation of disease was metastatic in 71 patients, relapsed case in 29 patients and 4 patients 
had unresectable disease. Baseline serum ALP level, CEA level and CA 19-9 level was above 
normal level in 39 (37.1%), 40 (38.5%) and 69 (66.3%) patients respectively. Eighty (77%) 
patients had either elevated CEA or CA 19-9 level. Most of the patients had good physical 
performance status. According to the inclusion criteria, none of the patients received prior 
systemic chemotherapy or radiotherapy.  
 
Prognostic Impact of Clinicopathologic Variables and Tumor Marker 
After a median follow-up duration of 32 months, 90 death events and 80 progression events 
occurred. The median TTP was 6.8 months (95% CI, 5.6 - 8.0) and the median OS was 13.8 
months (95% CI, 10.9 - 16.7). Overall response rate (RR) was 27.9% and 42.3% of patients 
showed stable disease. Baseline ECOG performance status 2 (4.7 months vs. 8.9 months in 
ECOG performance status 0, p = 0.078), elevated CEA level (5.1 months vs. 7.9 months, p = 
0.015) and elevated ALP level (5.4 months vs. 7.6 months, p = 0.039) were associated with poor 
TTP (Table 3). Liver metastasis and Initial metastatic presentation was not associated with TTP. 
In the multivariate analysis using Cox proportional hazard model, elevated baseline CEA level 
(adjusted HR 1.71, p = 0.025) and ALP level (adjusted HR 1.60, p = 0.050) were associated 
with poor TTP. There was no predictive role of CEA or CA 19-9 level based on best response 
assessed by RECIST criteria. In terms of OS, poor ECOG performance status, initial metastatic 
presentation, elevated ALP level, elevated CEA level and elevated CA 19-9 level (above 370 
U/mL) were associated with worse prognosis in univariate analysis (Table 3).  
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Table 2. Patient characteristics 
 Number of patients (%)  (N = 104) 
Age  
 Median (range) 59 (31 - 76) 
≥ 65 years 29 (27.9%) 
Sex  
 Male 60 (57.7%) 
 Female 44 (42.3%) 
Primary site  
 Intrahepatic cholangiocarcinoma 57 (54.8%) 
 Gall bladder cancer 33 (31.7%) 
 Extrahepatic cholangiocarcinoma 11 (10.6%) 
 Ampulla of vater cancer 3 (2.9%) 
Initial presentation  
 Metastatic 71 (68.3%) 
 Relapsed 29 (27.9%) 
 Unresectable 4 (3.8%) 
Metastasis  
 Liver 59 (56.7%) 
 Lymph node 53 (51.0%) 
 Peritoneal seeding 20 (19.2%) 
 Lung 9 (8.7%) 
Histologic grade  
 Well differentiated 5 (4.8%) 
 Moderately differentiated 20 (19.2%) 
 Poorly differentiated 6 (5.8%) 
 Unknown 73 (70.2%) 
ECOG PS  
 0 11 (10.6%) 
 1 89 (85.6%) 
 2 4 (3.8%) 
ALP (N = 103)  
 < 115 IU/L 64 (62.1%) 
 ≥ 115 IU/L 39 (37.9%) 
8 
CEA  
 < 5 ng/mL 64 (61.5%) 
 ≥ 5 ng/mL 40 (38.5%) 
CA 19-9 (N = 103)  
 < 37 U/mL 34 (33.0%) 
 ≥ 37 U/mL 69 (67.0%) 
 ≥ 370 U/mL 46 (44.7%) 
Abbreviations: PS, performance status 
 
 
Prognostic Implication of Gene polymorphism 
We analyzed 11 germline polymorphisms within 4 genes. Among variable gene polymorphism, 
only XRCC1 polymorphism in codons 194 had a prognostic role in OS (Table 4). The genotype 
of XRCC1 codons 194 C/T and T/T showed poorer OS compared to C/C (17.1 months vs. 10.6 
months, p = 0.053). However, XRCC1 194 polymorphism did not have a prognostic role in 
terms of TTP and response rate was similar between each group. To examine whether XRCC1 
194 polymorphism was associated with poor OS, we used Cox proportional hazard model in a 
forward stepwise manner. Multivariate analysis revealed that XRCC1 194 polymorphism had a 
prognostic role in OS (Table 5). XRCC1 194 C/T and T/T had a poor OS compared to C/C 
(adjusted HR 1.59, p = 0.048). Baseline elevated CEA level and ALP level was also a negative 











Table 3. Univariate analysis of progression free survival and overall survival 
Variable  TTP (95% CI) p-value OS (95% CI) p-value 
Age ≥65 years 7.4 (5.2 - 9.5) 0.54 12.9 (8.1 - 17.8) 0.72 
 <65 years 6.7 (5.2 - 8.2)  13.8 (10.4 - 17.3)  
Sex  Male 6.9 (5.4 - 8.5) 0.80 13.7 (9.8 - 17.6) 0.71 
  Female 6.6 (4.7 - 8.5)  13.5 (9.6 - 17.3)  
Primary site Intrahepatic 6.6 (5.0 - 8.2) 0.64 12.0 (8.8 - 15.3) 0.15 
 Others 7.0 (5.2 - 8.8)  16.1 (11.0 - 21.3)  
Initial 
presentation 
Metastatic 6.2 (5.0 - 7.5) 0.24 11.1 (8.5 - 13.8) 0.020 
Others 7.8 (5.4 - 10.2)  18.5 (12.3 - 24.6)  
Liver metastasis Present 6.4 (5.1 - 7.8) 0.50 12.2 (8.8 - 15.5) 0.22 
Absent 7.3 (5.3 - 9.3)  15.3 (10.8 - 19.8)  
ECOG PS 0 8.9 (5.4 - 12.3) 0.078 
vs. 2 
24.8 (14.7 - 34.9) 0.048 
vs. 2 
 1 6.7 (5.4 - 8.1) 0.34 
vs. 0 
12.5 (9.6 - 15.4) 0.024 
vs. 0 
 2 4.7 (1.9 - 7.5) 0.45 
vs. 1 
7.2 (4.3 - 10.2) 0.68 
vs. 1 
ALP ≥ 115 IU/L 5.4 (3.4 - 7.4) 0.039 9.4 (5.9 - 12.9) 0.006 
 < 115 IU/L 7.6 (6.2 - 9.0)  16.2 (12.3 - 20.2)  
CEA ≥ 5 ng/mL 5.1 (4.0 - 6.2) 0.015 8.5 (6.1 - 11.0) 0.002 
 < 5 ng/ml 7.9 (6.1 - 9.7)  17.3 (13.0 - 21.6)  
CA 19-9 ≥ 37 U/mL 6.7 (5.1 - 8.3) 0.49 12.2 (9.1 - 15.3) 0.15 
 < 37 U/mL 7.3 (5.5 - 9.1)  17.1 (11.0 - 23.2)  
CA 19-9 ≥ 370 U/mL 6.4 (4.8 - 7.9) 0.51 10.2 (7.7 - 12.7) 0.043 
 < 370 U/mL 7.2 (5.5 - 9.0)  16.7 (12.0 - 21.4)  






Table 4. Genetic polymorphism and treatment outcomes  
Gene Polymorphism (N) TTP (95%CI) p -value OS (95%CI) 
p - 
value 
XRCC1 194 CC (51) 7.4 (5.5 - 9.3) 0.32 17.1 (12.1 - 22.1) 0.053 
CT + TT (53) 6.0 (4.8 - 7.3)  10.6 (7.7 - 13.5)  
XRCC1 280 GG (82) 6.4 (5.3 - 7.7) 0.36 12.5 (9.7 - 15.3) 0.19 
GA (22) 8.2 (4.9 - 11.5)  18.5 (9.8 - 27.1)  
XRCC1 399 GG (60) 7.0 (5.5 - 8.5) 0.67 14.4 (10.1 - 18.6) 0.91 
GA + AA (44) 6.6 (4.8 - 8.4)  13.1 (9.3 - 16.9)  
TS 5’UTR High expression* (74) 6.9 (5.5 - 8.3) 0.90 14.5 (11.0 - 18.1) 0.44 
 Low expression* (29) 7.0 (4.6 - 9.4)  12.0 (7.3 - 16.8)  
TS 6-bp  
deletion 
+6/+6 or +6/-6 (25) 6.1 (3.4 - 8.7) 0.27 12.5 (6.2 - 18.9) 0.64 
-6/-6 (79) 7.1 (5.8 - 8.5)  14.0 (10.8 - 17.2)  
ERCC1 118 CC (53) 7.3 (5.3 - 9.2) 0.50 15.4 (10.8 - 19.9) 0.44 
 CT + TT (51) 6.4 (4.9 - 7.9)  12.1 (8.6 - 15.5)  
ERCC1 8092 CC (59) 6.8 (5.5 - 8.1) 0.82 14.4 (10.5 - 18.4) 0.62 
 CA + AA (45) 6.7 (4.7 - 8.8)  12.6 (8.7 - 16.5)  
XPD 156 CC (29) 7.5 (5.0 - 10.0) 0.54 16.2 (9.3 - 23.0) 0.58 
 CA + AA (75) 6.6 (5.2 - 8.0)  12.5 (9.8 - 15.2)  
XPD 312 GG (99) 7.0 (5.8 - 8.3) 0.087 13.7 (10.8 - 16.7) 0.79 
 GA (5) 3.5 (0.0 - 7.5)  14.7 (0.0 - 32.7)  
XPD 751 AA (96) 7.1 (5.8 - 8.4) 0.12 13.6 (10.7 - 16.5) 0.90 
 AC (8) 4.4 (2.4 - 6.5)  15.1 (3.7 - 26.5)  








Table 5. Multivariate analysis of overall survival  
Variable  Adjusted HR (95% CI) p-value 
CEA < 5 ng/ml 1 0.003 
 ≥ 5 ng/mL 1.95 (1.26 - 2.99)  
ALP < 115 IU/L 1 0.003 
 ≥ 115 IU/L 1.94 (1.26 - 3.01)  
XRCC1 194 CC 1 0.037 
 CT + TT 1.59 (1.03 - 2.44)  
Abbreviations: HR, hazard ratio; CI, confidence interval 
 
 
CEA and CA 19-9 Change 
 We next evaluated whether decrease in serum CEA and CA 19-9 level after first cycle of 
chemotherapy can predict treatment outcomes. Among 69 patients with baseline elevated CA 
19-9 level, CA 19-9 level after first cycle of chemotherapy was measured in 67 patients (97%). 
36 patients among 40 patients (90%) with baseline elevated CEA level had CEA level after first 
cycle of chemotherapy. In patients with baseline CA 19-9 above normal range, decrease ≥ 30% 
was associated with favorable prognosis, respectively for TTP (5.0 months vs. 8.6 months, p = 
0.015) and OS (7.9 months vs. 18.4 months, p < 0.001) (Figure 1). Similar results were obtained 
with CEA level, patients with CEA decrease ≥ 30% showed favorable TTP (4.2 months vs. 7.7 
months, p = 0.012) and OS (6.8 months vs. 14.7 months, p = 0.024) (Figure 2). Patients with 
tumor marker decline ≥ 30% was also associated with better responses to chemotherapy (Table 
6). Patients with CA 19-9 decrease ≥ 30% showed RR in 55% compared to 8% in patients with 
CA 19-9 decrease < 30%. RR was 89% for patients who had CEA decline ≥ 30% compared to 






Figure 1. CA 19-9 change and Survival 
A: CA 19-9 change and TTP 




Figure 2. CEA change and Survival 
A: CEA change and TTP 























CR 1 (2.6%) 0 (0.0%) <0.001 0 (0.0%) 1 (11.1%) <0.001 
PR 2 (5.3%) 16 (55.2%)  4 (14.8%) 7 (77.8%)  
SD 19 (50.0%) 9 (31.0%)  13 (48.1%) 1 (11.1%)  
PD 8 (21.1%) 3 (10.3%)  6 (22.2%) 0 (0.0%)  
N/A 8 (21.1%) 1 (3.4%)  4 (14.8%) 0 (0.0%)  
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, 





The aim of our study is to evaluate the predictive and prognostic role of tumor markers (CEA 
and CA 19-9) and gene polymorphism in patients with advanced biliary tract cancer. As biliary 
tract cancer is a rare cancer worldwide, predictive and prognostic factors has not been clearly 
defined nor have been validated. Older age, large tumor volume, metastatic disease, intrahepatic 
cholagiocarcinoma, liver metastasis, ECOG performance status and ALP level have been 
proposed as a prognostic factor in advanced biliary tract cancer (12, 15). Using our homogenous 
cohort of patients treated with first-line S-1 plus cisplatin, we found that baseline CEA level and 
XRCC1 exon 194 polymorphism is associated with treatment outcome. In addition, we also 
evaluated that CEA and CA 19-9 decline after first cycle of chemotherapy has both predictive 
and prognostic role.  
 Among variable tumor markers, CEA and CA 19-9 are the two markers that have been most 
studied in biliary tract cancer. Serum CEA level and CA 19-9 have a role in diagnosis of 
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cholangiocarcinoma in patients with primary sclerosing cholangitis (16-19). While diagnostic 
value of tumor markers have been widely evaluated and are clinically used, their predictive and 
prognostic roles have not been well studied. In our study, patients with baseline CEA ≥ 5ng/ml 
had poor TTP and OS compared to patients with CEA < 5ng/ml. Although CA 19-9 did not have 
a prognostic role in TTP, patients with CA 19-9 ≥ 370U/ml had a worse OS compared to 
patients with CA 19-9 < 370U/ml. In multivariate analysis only elevated CEA was associated 
with poor OS and there was no prognostic role of CA 19-9. These results are in line with studies 
performed in colorectal cancer and pancreatic cancer. In colorectal cancer, patients with CEA ≥ 
5.0ng/mL had an adverse impact on survival independently of tumor stage (20, 21). Elevated 
CA 19-9 level was associated with poorer survival in patients with pancreatic cancer (22-24).  
We also found out that decline in tumor marker after first cycle of chemotherapy can predict 
chemotherapy response and patients prognosis. CA 19-9 decrease ≥ 30% after first cycle of 
chemotherapy was associated with improved TTP and OS in patients with elevated baseline CA 
19-9. CA 19-9 decline was also associated with better tumor response. Similar results were 
obtained using CEA level instead of CA 19-9 level. In patients with elevated baseline CEA level, 
CEA decrease ≥ 30% after first cycle of chemotherapy was associated with improved TTP, 
prolonged OS and better tumor response to chemotherapy. Clinical significance of tumor marker 
change was studied in pancreatic cancer. In advanced pancreatic cancer, decline in CA 19-9 
level after chemotherapy was associated with improved survival (25, 26). CA 19-9 rise after 
second cycle of chemotherapy also served as a negative predictive factor (27). Tumor response 
assessment using RECIST criteria is usually measured after two to three months after the start 
of the chemotherapy because earlier changes are seldom significant. Our result shows that tumor 
maker measurement after the first cycle of chemotherapy (3 weeks after the start of the 
chemotherapy) can predict tumor response as well as survival. Earlier prediction of treatment 
efficacy and prognosis by tumor marker measurement can help physician’s decision and can 
prevent patients from unnecessary, ineffective treatment.  
 XRCC1 is a DNA repair gene involved in the repair of single strand breaks and base excision 
repair (28). We analyzed the prognostic role of XRCC1 polymorphism in codon 194, 280 and 
15 
399. Only polymorphism in XRCC1 codon 194 had a prognostic role and there was no 
prognostic role for codon 280 and 399. Patients with XRCC1 codon 194 C/T and T/T had a poor 
OS compared to C/C. In line with our study, preclinical studies showed that cells with XRCC1 
194 C/C received higher damage to genotoxics compared to C/T and T/T (29, 30). Biliary tract 
cancer in XRCC1 194 C/C patients may have higher damage to chemotherapy agent. However 
the studies used NNK (nicotine-derived nitrosamine ketone) and bleomycin for genotoxic agent, 
and there is no preclinical data on relationship between XRCC1 codon polymorphism and S-1 
or cisplatin chemotherapy.  
The major limitation of this study is that only patients with measurable tumor lesion and those 
treated with first line S-1 and cisplatin were included. As XRCC1 is associated with DNA repair, 
prognostic role of XRCC1 polymorphism may be limited to specific chemotherapy agent. 
However, there is no relationship between specific chemotherapy and decline of tumor marker. 
This is the first study to evaluate the effect of tumor marker change in patients with biliary tract 
cancer. Our findings need further validation in an independent cohort, especially for patients 
treated with gemcitabine based chemotherapy and patients without measurable tumor lesion. 
In conclusion, baseline CEA level and polymorphism of XRCC1 has a prognostic role in 
advanced biliary tract cancer. While there was no prognostic role for baseline CA 19-9 level, CA 
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서론: 담도계암은 발생빈도가 낮은 악성종양으로, 진행성 담도계암에서의 예측인자
와 예후인자는 확립되지 않았다. 우리는 진행성 담도계암에서 종양인자, 종양인자의 
변화, 유전자 다형성 (genetic polymorphism)의 예측 인자 혹은 예후 인자로서의 역할
을 확인하려고 한다.  
 
대상 및 방법: 일차 항암치료제로 S-1과 cisplatin의 병용요법을 치료받은, 병리적으
로 확진된 전이성 혹은 재발성 담도암 환자를 대상으로 하였다. 우리는 각 인자에 
따른 진행 소요기간 (TTP) 및 생존기간 (OS)을 비교하려고 하였다.  
 
결과: 전체 104명의 환자 중 69 (66.3%)명에서 기저 CA 19-9 수치가 상승되어 있었
으며 40 (38.5%)명의 환자에서 기저 CEA 수치가 상승되어 있었다. 전체 환자 중 80 
(77%)명에서 기저 CA 19-9 수치 혹은 CEA 수치가 상승되어 있었다. 다변량 분석결
과 기저 CEA 수치가 높은 환자에서 진행 소요기간 및 생존 기간이 짧았다. 다변량 
분석 결과 기저 CA 19-9 수치는 진행 소요기간과 생존 기간에 영향을 미치지 않았
다. PCR- RFLP (Restriction Fragment Length Polymorphism)을 이용하여 4개의 유전자에
서 11개의 유전자 다형성을 확인하였다. 이들 중 XRCC1 exon 194번의 유전자 다형
성만이 생존기간에 영향을 미치는 예후 인자였다. 다변량 분석결과 XRCC1 194의 
C/T와 T/T가 C/C에 비해 불량한 생존기간을 나타냄을 확인하였다 (adjusted HR 1.59, 
p = 0.048). 기저 CA 19-9 수치가 높은 환자를 대상으로, 1회 항암치료 후 CA 19-9 수
치가 30% 이상 감소한 환자에서 그렇지 않은 환자에 비해 진행 소요기간 (5.0 vs. 
8.6 months, p = 0.015) 및 생존기간 (7.9 vs. 18.4 months, p < 0.001)의 연장을 확인 하였
으며 반응률이 더 좋았다. CEA 수치 변화를 이용하여도 비슷한 결과를 얻을 수 있
었다.  
21 
결론: 기저 CEA 수치와 XRCC1 유전자 다형성은 진행성 담도계암 환자에서 예후
인자였다. CA 19-9 혹은 CEA 수치가 1회 항암치료 후 30% 이상 감소하는 것은 
좋은 예후인자 및 예측인자였다.  
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